A need for evidence-based clinical practice guidelines for the use of heparins in the elderly

Isabelle Gouin-Thibault1,2
Virginie Siguret1,2
Eric Pautas2,3
1Assistance Publique Hôpitaux de Paris, Laboratoire d'Hématologie, Hôpital Charles Foix, Paris, France; 2Université Paris Descartes, INSERM U, Paris, France; 3Assistance Publique Hôpitaux de Paris, Unité de Gériatrie Aigue, Hôpital Charles Foix, Paris, France

Abstract: Low-molecular-weight heparins (LMWHs) have been widely studied in pivotal clinical trials or in several meta-analyses. However, the safety and optimal use of LMWHs in high-risk patients such as the very elderly remains uncertain since these patients are usually excluded from clinical trials. In terms of LMWHs in the elderly, the main concerns are renal failure and the risk of accumulation. A clinical approach consisting of a LMWH dose reduction in the elderly should be considered with great caution in terms of efficacy, since it has been tested neither in the treatment of VTE nor in VTE prophylaxis. If monitoring is considered in patients receiving therapeutic dose LMWHs, appropriate target ranges for peak anti-Xa activity levels should be used and so far, no anti-Xa activity-based guidelines have been issued. Moreover, no data support any laboratory monitoring in elderly patients treated with prophylactic dose LMWHs.

Keywords: elderly patients, low-molecular-weight heparin, renal insufficiency, evidence-based medicine

The number of elderly patients who require anticoagulant therapy is rising steadily as the aging of the population is causing increases in the prevalence of venous and arterial thromboembolism. Due to the higher risk of bleeding, managing anticoagulants in these frail patients may be challenging. Among anticoagulants used to prevent or treat thromboembolism events, low-molecular weight heparins (LMWHs) have been widely studied in pivotal clinical trials or in several meta-analyses. However, despite their wide development and use, the safety and optimal use of LMWHs in high-risk patients such as the very elderly, remain uncertain since these patients are usually excluded from clinical trials. So far, only one study has been conducted in elderly patients with moderate to severe renal impairment: the “Innohep® in Renal Insufficiency Study” (IRIS). Unfortunately, this trial was prematurely stopped thus the results are un conclusive.1

In a recent issue of this Journal, Robert-Ebadi et al thoroughly reviewed the risk/benefit ratio of the use of anticoagulation in elderly patients and considered different approaches to improve safety in this population.2 One concern raised in this review is the increased risk of accumulation and bleeding in patients with impaired renal function receiving LMWHs, since LMWHs are mainly excreted by the kidney.

In patients with severe renal impairment (creatinine clearance < 30 mL/min) who require therapeutic anticoagulation, Robert-Ebadi et al suggest using unfractionated heparin instead of LMWHs. If LMWH is used in these patients, they suggest ‘LWMH with dose reduction (1/2 dose).’ These recommendations are in agreement with those...
of the Eighth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic and Thrombolytic Therapy. It is noteworthy that the ACCP recommendations on this topic are weak with a low quality of evidence (grade 2C) and are mostly based on studies with enoxaparin. So far, the efficacy and safety of LMWHs used at reduced initial dosages have not been evaluated in the treatment of acute venous thromboembolism (VTE). A dose-adjustment proposal according to renal function has only been investigated in patients with acute coronary syndrome receiving enoxaparin: the authors of the study observed that a dose reduction leading to low anti-Xa levels (<0.5 U/mL) may increase the risk of mortality and recurrent ischemic events.

A dose reduction is also suggested by Robert-Ebadi et al in patients receiving prophylactic doses of LMWHs in medical setting. The results of the two main clinical trials assessing the use of enoxaparin (MEDENOX) and dalteparin (PREVENT) for the prevention of venous thromboembolism in acutely ill medical patients do not support such an option. Indeed, in the MEDENOX study, the daily 40 mg enoxaparin dosage was particularly effective in the group of patients older than 80 years (the risk reduction of VTE was 87% in patients 80 years and older as compared with 63% in the general study population), while the daily 20 mg dosage was similar to placebo. Similarly, in the PREVENT study, the relative treatment effect of dalteparin was not attenuated when adjusted for age with a 48% reduction of VTE events in patients aged 75 years and older treated with dalteparin compared with patients receiving placebo, without an increase in major hemorrhages. Thus, due to the lack of clinical evidence, we think that the decision to use reduced therapeutic or prophylactic dosages should be considered with great caution since it could be beneficial in terms of safety but deleterious in terms of efficacy.

To date it has not been demonstrated that plasma anti-Xa activity levels correlate with clinical outcomes. Dose finding studies with LMWHs used at curative doses have demonstrated that increasing the dose was associated with higher anti-Xa activity levels and an increased risk of major bleeding. Monitoring of anti-Xa activity in patient treated with therapeutic LMWH dose may be recommended to detect an overdosage and/or accumulation in patients with renal impairment. In their review, Robert-Ebadi et al suggest considering anti-Xa monitoring in elderly patients treated with therapeutic doses of LMWH and to use the target ranges of 0.6–1 IU/mL for twice-daily LMWH and 1–2 IU/mL for once-daily LMWHs. These ranges are those cited by Kearon et al in the Antithrombotic therapy for venous thromboembolism disease chapter of the ACCP guidelines. The use of these conservative target ranges may lead to a misinterpretation of the anti-Xa activity. Indeed, due to a better understanding of the pharmacodynamic profile of each LMWH preparation, more accurate target levels for anti-Xa activity have been published, especially by Hirsh et al in the Parenteral anticoagulants chapter of the same issue of the ACCP guidelines: >1.0 with enoxaparin; 0.87 IU/mL with tinzaparin; 1.34 IU/mL with once-daily and 1.01 with twice-daily nadroparin; 1.05 IU/mL with once daily and 0.59 IU/mL with twice-daily dalteparin. Moreover, it is noteworthy that so far, no dose adjustment guidelines based on anti-Xa activity are available.

Finally, in patients with severe renal impairment treated with prophylactic doses of LMWHs, Robert-Ebadi et al suggest to monitor anti-Xa activity to detect an accumulation based on Mahé et al study. However in the latter study, the authors came to the conclusion that ‘the results do not support laboratory monitoring in patients treated with prophylactic doses of enoxaparin, even older patients with impaired renal function and/or low body-weight.’ Indeed, they showed that in 125 acutely ill medical inpatients (mean age 87 years) receiving daily 4000 IU of enoxaparin up to 10 days, the mean anti-Xa activity value was slightly but significantly higher during the course than at the beginning of therapy. The difference in mean anti-Xa activity levels between patients with versus those without severe renal impairment was only of 0.11 IU/mL and the mean peak anti-Xa value in patients with severe renal impairment was of 0.72 IU/mL, i.e., levels of anti-Xa activity not clearly associated with an increased risk of bleeding.

In terms of LMWHs in the elderly, renal failure and the risk of accumulation is the main concern. However, other situations such as extreme body weight are also of concern. For thromboprophylaxis, a strong negative correlation was found between total body weight and anti-Xa levels in elderly inpatients treated with fixed-dose enoxaparin and nonelderly obese patients treated with fixed-dose enoxaparin and nadroparin. Due to the paucity of data, no validated recommendations in these situations are available.

In conclusion, the approach consisting of a LMWH dose reduction in the elderly should be considered with great caution in terms of efficacy, since it has been tested neither in the treatment of VTE nor in VTE prophylaxis. If monitoring is considered in patients receiving therapeutic dose LMWHs, appropriate target ranges for peak anti-Xa levels should be used and so far, no anti-Xa based guidelines have been issued. Finally, no data support any laboratory monitoring in elderly patients treated with prophylactic doses LMWHs.
A need for evidence-based clinical practice guidelines

Disclosures
The authors report no conflicts of interest in this work.

References